Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
about
Probiotics for maintenance of remission in ulcerative colitisUrinary phthalate metabolite concentrations among men with inflammatory bowel disease on mesalamine therapyMesalazine in inflammatory bowel disease: a trendy topic once again?Efficacy of long-term 4.0 g/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitisLong-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis.A new look at a mainstay ulcerative colitis therapyManagement of arthropathy in inflammatory bowel diseases.The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitisEmerging drugs for the treatment of ulcerative colitisUpdate on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.Treatment of inflammatory bowel disease: a review of medical therapy.Quality of care for patients with inflammatory bowel disease in East China.JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokinesIndividually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease.Advances in the pathogenesis and treatment of IBDPatient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine.Second Korean guidelines for the management of ulcerative colitis.Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis.Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel diseaseManagement of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.Is mesalamine safe?Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies.Navigating the complexity of ulcerative colitis: challenging case example.Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.Evaluation of the drug-induced lymphocyte stimulation test for diagnosing mesalazine allergy.
P2860
Q24234400-68848B9C-749F-4D9D-BF04-EFDDCD2D427FQ28397446-C16E5F46-D46F-4226-9A55-56211BCB8D94Q33779797-FE5C93BA-5507-400F-BF62-267FD323CB68Q34062169-2E101DCC-AFA8-48EC-B90B-F40954302140Q34273329-8632B27A-1445-4439-8583-3E6093ED336BQ34420368-05F7C567-0A27-4EBA-8120-B4FC8D6A13CDQ34940520-24D970C2-6364-4033-8E46-53BB6A149268Q35091366-6436E51F-0408-4141-802E-FA3343269577Q35859785-9C1C7071-51EE-48B5-BC55-C6856080C8FBQ36039436-9CC68B80-EAE8-45FD-A4BA-CF8046996C0CQ36144377-2AD1A531-C646-4C7C-98B8-73D3E8824E80Q36815176-FA6F836B-3C8F-4F88-A4FF-3C2997C5E89EQ36930800-71E2BD59-39B2-40CC-8DEC-E62F4ACAF069Q37058862-BD17519E-2C16-4CB5-9306-88D686927F74Q37059857-358E92B4-F281-40C7-897A-A6933E5C204EQ37148745-42C39EDD-03BC-41AE-BB88-800EC556866DQ37149572-4B1E8FF4-A722-4483-AF50-57B2456FDF47Q37219854-BB378EEE-3E68-4196-B00C-F8668525F2B9Q37423752-287224F7-78BB-47D0-8158-233A42EAA81DQ37662503-12497E93-93DC-42C1-AA15-AA0B915E99CDQ37691599-84D62521-FAF5-4281-85E1-83B2C09F349AQ38288749-8965C5F1-86D4-4E37-994A-FD2534508039Q38660544-3EFC6269-A0B8-46BB-977B-59E52190D4B2Q38735146-AA43B2A1-E74E-4B58-8B0B-BB3D44AF2FC3Q42140692-BE50EB51-12E6-4E9F-AA5B-860C70B65FEBQ42385055-75F1D9D1-93C6-4B37-9CD2-281AC5E7EF21Q42648170-4F1D0ABA-4815-4F55-98D6-096BC7524FBAQ42877648-27A8BE39-AE38-4D0E-BE26-40EDD50D3FA5Q55000667-13D07104-2E4A-4DC8-A90C-1D7D9D82132B
P2860
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
@ast
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
@en
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
@en-gb
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
@nl
type
label
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
@ast
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
@en
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
@en-gb
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
@nl
prefLabel
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
@ast
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
@en
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
@en-gb
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
@nl
P2860
P1476
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
@en
P2093
John K MacDonald
Lloyd R Sutherland
P2860
P356
10.1002/14651858.CD000544.PUB2
P577
2006-04-19T00:00:00Z